Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes

William Blair analyst Myles Minter has maintained their neutral stance on VIGL stock, giving a Hold rating on May 28.

Myles Minter has given his Hold rating due to a combination of factors surrounding Vigil Neuroscience Inc’s recent developments. The Phase II IGNITE study for iluzanebart, a key compound, did not meet its efficacy endpoints, which was anticipated and thus did not affect the valuation of the company, especially in light of the upcoming acquisition by Sanofi.
Despite the disappointing trial results, the acquisition terms already accounted for the return of iluzanebart to Amgen, meaning the study’s outcome does not impact the acquisition deal expected to close in the third quarter of 2025. The current valuation of Vigil’s shares, primarily driven by VG-3927 and cash reserves, aligns with the acquisition offer, justifying the Hold rating as the shares appear fairly valued with some potential upside from contingent value rights.

In another report released on May 28, H.C. Wainwright also downgraded the stock to a Hold with a $8.00 price target.